Quadrant Management

Quadrant Management is a private equity firm based in New York, founded in 1978. Specializing in lower-middle market investments, the firm focuses on providing capital for investment and acquisition processes, as well as management services. Quadrant Management targets companies that are often in restructuring situations, leveraging its expertise to enhance operational efficiency and drive growth within its portfolio. The firm's approach emphasizes a hands-on management style to support the development of the businesses it invests in.

Weston Quasha

Managing Director and Investment Executive

4 past transactions

Vantem Global

Venture Round in 2022
Vantem Global specializes in manufacturing a proprietary structural insulated panel system for efficient construction. Their platform enables the factory-based production of volumetric modules, resulting in weather-resistant, thermally efficient, and finish-ready panels for constructing homes. This method reduces construction costs, enhances energy efficiency, and accelerates project delivery times.

Wandercraft

Series C in 2022
Wandercraft is a robotics company that develops self-balancing robotic exoskeletons to enable paralyzed users to stand and walk hands-free, without crutches. Its flagship exoskeleton, Atalante, is a commercial device designed for daily life and rehabilitation, CE-marked in 2019 and marketed to European rehab hospitals to support gait re-learning. The company combines algorithmics, AI, robotics, production, clinical, marketing and sales to deliver a full-stack solution and aims to bring a realistic, autonomous walking device beyond lab prototypes. The exoskeleton uses motors at each joint controlled by a computing unit running software that computes robotic algorithms every millisecond to replicate a human gait, enabling paraplegic individuals to regain autonomy during daily activities.

SyncThink

Seed Round in 2018
SyncThink Inc. is a neuro-technology company based in Palo Alto, California, that specializes in eye-tracking technology for brain health analytics. Founded in 2009 by neurosurgeon Dr. Jamshid Ghajar, the company has developed the EYE-SYNC device, a non-invasive, head-mounted eye-tracking system designed to provide medical professionals with objective metrics related to visual attention and dynamic orientation. EYE-SYNC performs a rapid, 60-second assessment to identify ocular motor impairments and vestibular dysfunction, which are critical components in concussion evaluation. This technology is utilized by various university athletic departments and medical facilities, including Stanford University and Massachusetts General Hospital, for brain health assessment and recovery monitoring. SyncThink's innovations are backed by numerous partnerships with leading research institutions and have received FDA approval, making them applicable in military and athletic contexts as well as in broader applications related to attention development and brain performance. The company holds multiple patents related to its technology and analytics, further solidifying its position in the neuro-diagnostics field.

SyncThink

Seed Round in 2011
SyncThink Inc. is a neuro-technology company based in Palo Alto, California, that specializes in eye-tracking technology for brain health analytics. Founded in 2009 by neurosurgeon Dr. Jamshid Ghajar, the company has developed the EYE-SYNC device, a non-invasive, head-mounted eye-tracking system designed to provide medical professionals with objective metrics related to visual attention and dynamic orientation. EYE-SYNC performs a rapid, 60-second assessment to identify ocular motor impairments and vestibular dysfunction, which are critical components in concussion evaluation. This technology is utilized by various university athletic departments and medical facilities, including Stanford University and Massachusetts General Hospital, for brain health assessment and recovery monitoring. SyncThink's innovations are backed by numerous partnerships with leading research institutions and have received FDA approval, making them applicable in military and athletic contexts as well as in broader applications related to attention development and brain performance. The company holds multiple patents related to its technology and analytics, further solidifying its position in the neuro-diagnostics field.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.